Two Phase 3 Trials of Baricitinib for Alopecia Areata.
Brett KingManabu OhyamaOhsang KwonAbraham ZlotogorskiJustin KoNatasha A MesinkovskaMaria HordinskyYves DutroncWen-Shuo WuJill McCollamChiara ChiasseriniGuanglei YuSarah StanleyKatrin HolzwarthAmy M DeLozierRodney Sinclairnull nullPublished in: The New England journal of medicine (2022)
In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks. Longer trials are required to assess the efficacy and safety of baricitinib for alopecia areata. (Funded by Eli Lilly under license from Incyte; BRAVE-AA1 and BRAVE-AA2 ClinicalTrials.gov numbers, NCT03570749 and NCT03899259.).